Drug
Cu(II)ATSM
Cu(II)ATSM is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Other(2)
Detailed Status
Completed3
unknown2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
unknown240%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_1
ALS Treatment Extension Study
NCT03136809
completedphase_2
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
NCT04313166
completedphase_1
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
NCT03204929
completedphase_1
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NCT02870634
unknownphase_2
CuATSM Compared With Placebo for Treatment of ALS/MND
NCT04082832
Clinical Trials (5)
Showing 5 of 5 trials
NCT03136809Phase 1
ALS Treatment Extension Study
NCT04313166Phase 2
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
NCT03204929Phase 1
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
NCT02870634Phase 1
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NCT04082832Phase 2
CuATSM Compared With Placebo for Treatment of ALS/MND
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5